ALGS -12.49% 7D on Promising HBV and MASH Therapies

On NOV 17 2025, ALGO (ALGS) dropped by 5.16% within 24 hours to reach $0.1512, with a 7-day decline of 12.49%, a 1-month drop of 15.05%, and a 1-year decrease of 54.95%. Despite the downward trend, recent developments in the company’s drug pipeline have positioned Aligos Therapeutics as a name of interest in the biopharma sector.

Promising Trial Data for HBV and MASH

Aligos Therapeutics reported compelling data from its ongoing clinical trials at the Jefferies London Healthcare Conference on November 17, 2025. Pevifoscorvir, the company’s investigational therapy for chronic hepatitis B virus (HBV), demonstrated superior performance in suppressing HBV DNA and reducing antigen levels compared to standard treatments. The drug also showed no evidence of resistance and a favorable safety profile. A global Phase II trial is currently underway, with interim results expected in 2026 and top-line data in 2027.

In parallel, Aligos highlighted progress in its MASH and obesity programs. ALG-009, another key candidate, has shown enhanced potency and metabolic benefits, with strong potential for treating metabolic dysfunction-associated steatohepatitis (MASH). These results suggest that the company is making meaningful strides in addressing significant unmet medical needs in liver and viral diseases.

Strategic R&D and Clinical Development

Aligos’ approach is grounded in science-driven innovation, with a pipeline designed to tackle complex conditions like HBV and MASH. The company’s leadership emphasized its commitment to developing best-in-class therapies during its recent conference appearance, reinforcing its long-term vision of improving patient outcomes through advanced therapeutic solutions.

The ongoing clinical development of these therapies reflects Aligos’ focus on building a robust portfolio that targets chronic and high-prevalence diseases. With both Pevifoscorvir and ALG-009 in active trials, the company is positioned to generate key data points in the near term that could influence investor sentiment and market positioning.

Equity Incentive Grants for New Hires

On November 14, 2025, Aligos announced a stock option grant under its 2024 Inducement Plan to newly hired employees. The non-qualified stock options were issued as part of the company’s effort to attract and retain talent, in compliance with Nasdaq Listing Rule 5635(c)(4). The grant includes 23,600 shares, with an exercise price set at the closing stock price on the grant date. These options will vest over four years, with 25% vesting annually and the remainder vesting monthly, subject to continued employment.

This move underscores the company’s strategic investment in its workforce, aiming to support its clinical development goals and strengthen its operational capabilities. The equity inducements align with Aligos’ long-term growth strategy and its mission to deliver innovative therapies to patients in need.